Vitamin D deficiency may raise risk of getting COVID-19

In a retrospective study of patients tested for COVID-19, researchers at the University of Chicago Medicine found an association between vitamin D deficiency and the likelihood of becoming infected with the coronavirus.

"Vitamin D is important to the function of the immune system and vitamin D supplements have previously been shown to lower the risk of viral respiratory tract infections," said David Meltzer, MD, PhD, Chief of Hospital Medicine at UChicago Medicine and lead author of the study. "Our statistical analysis suggests this may be true for the COVID-19 infection."

The research team looked at 489 UChicago Medicine patients whose vitamin D level was measured within a year before being tested for COVID-19. Patients who had vitamin D deficiency (< 20ng/ml) that was not treated were almost twice as likely to test positive for the COVID-19 coronavirus compared to patients who had sufficient levels of the vitamin.

The study, Association of Vitamin D Status and Other Clinical Characteristics With COVID-19 Test Results, was published Sept. 3 in JAMA Network Open. Findings were previously reported on medRxiv, a preprint server for the health sciences.

Half of Americans are deficient in Vitamin D, with much higher rates seen in African Americans, Hispanics and individuals living in areas like Chicago where it is difficult to get enough sun exposure in winter.

"Understanding whether treating Vitamin D deficiency changes COVID-19 risk could be of great importance locally, nationally and globally," Meltzer said. "Vitamin D is inexpensive, generally very safe to take, and can be widely scaled."

Meltzer and his team emphasize the importance of experimental studies to determine whether vitamin D supplementation can reduce the risk, and potentially severity, of COVID-19. They also highlight the need for studies of what strategies for vitamin D supplementation may be most appropriate in specific populations. They have initiated several clinical trials at UChicago Medicine and with partners locally.

Meltzer DO, Best TJ, Zhang H, Vokes T, Arora V, Solway J.
Association of Vitamin D Status and Other Clinical Characteristics With COVID-19 Test Results.
JAMA Netw Open. 2020. doi: 10.1001/jamanetworkopen.2020.19722

Most Popular Now

Johnson & Johnson announces European Commissio…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the European Commission (EC), acting on behalf of the European Union (EU) Member States, has approved an Advance Pur...

BioNTech and Pfizer initiate rolling submission to…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a rolling submission to the European Medicines Agency (EMA) for BNT162b2, the lea...

Vir Biotechnology and GSK announce global expansio…

Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) announced the global expansion to Phase 3 of the COMET-ICE (COVID-19 Monoclonal antibody Eff...

Johnson & Johnson initiates pivotal global Pha…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, J...

COVID-19 Long-Acting AntiBody (LAAB) combination A…

AstraZeneca's long-acting antibody (LAAB) combination, AZD7442, will advance into two Phase III clinical trials in more than 6,000 participants at sites in and outside th...

COVID-19 vaccine AZD1222 clinical trial resumed in…

The Phase I/II clinical trial for the COVID-19 vaccine AZD1222 has resumed in Japan after discussion with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). ...

Adequate levels of vitamin D reduces complications…

Hospitalized COVID-19 patients who were vitamin D sufficient, with a blood level of 25-hydroxyvitamin D of at least 30 ng/mL (a measure of vitamin D status), had a signif...

Gilead Sciences signs joint procurement agreement …

Gilead Sciences (Nasdaq: GILD) and the European Commission signed a joint procurement agreement (JPA) that will enable rapid and equitable access to Veklury® (remdesivir)...

Protective antibodies persist for months in surviv…

People who survive serious COVID-19 infections have long-lasting immune responses against the virus, according to a new study led by researchers at Massachusetts General ...

Potential COVID-19 vaccines not affected by domina…

Vaccines currently being developed for COVID-19 should not be affected by recent mutations in the virus, according to a new study involving a University of York virologis...

Regeneron's REGN-COV2 antibody cocktail reduced vi…

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the first data from a descriptive analysis of a seamless Phase 1/2/3 trial of its investigational antibody cockta...

Popular COVID-19 conspiracies linked to vaccine 'h…

A new study of beliefs and attitudes toward COVID-19 in five different countries - UK, US, Ireland, Mexico and Spain - has identified how much traction some prominent con...